<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="38559">Cytochrome P450</z:chebi> 2E1 (CYP2E1) is a <z:chebi fb="0" ids="38559">cytochrome P450</z:chebi> enzyme that catalyzes the metabolism of toxic substrates </plain></SENT>
<SENT sid="1" pm="."><plain>CYP2E1 is upregulated in <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e>, including the <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> (<z:chebi fb="20" ids="15767">DCM</z:chebi>) mouse model </plain></SENT>
<SENT sid="2" pm="."><plain>Here, knockdown of CYP2E1 significantly ameliorated the <z:mp ids='MP_0002753'>dilated left ventricle</z:mp>, thin wall, and dysfunctional contraction in the cTnT(R141W) and adriamycin-induced <z:chebi fb="20" ids="15767">DCM</z:chebi> mouse models </plain></SENT>
<SENT sid="3" pm="."><plain>Interstitial <z:mp ids='MP_0003045'>fibrosis</z:mp>, poorly organized myofibrils, and <z:mp ids='MP_0011632'>swollen mitochondria</z:mp> with loss of cristae were improved in the myocardium of α-myosin heavy chain (MHC)-cTnT(R141W)×CYP2E1-silence double-transgenic mice when compared with the cTnT(R141W) transgenic mice </plain></SENT>
<SENT sid="4" pm="."><plain><z:mp ids='MP_0003674'>Oxidative stress</z:mp>, the activation of caspase 3 and caspase 9, the release of <z:chebi fb="1" ids="18070">cytochrome c</z:chebi>, and the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in the myocardium were significantly decreased in double-transgenic mice compared with the cTnT(R141W) transgenic mice </plain></SENT>
<SENT sid="5" pm="."><plain>In summary, the expression of CYP2E1 is upregulated in <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> and might be induced by hypoxemia in <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>The overexpression of CYP2E1 can enhance the metabolism of endogenous <z:chebi fb="3" ids="17087">ketones</z:chebi> to meet the energy demand of the heart in certain <z:mp ids='MP_0002054'>disease states</z:mp>, but the overexpression of CYP2E1 can also increase <z:mp ids='MP_0003674'>oxidative stress</z:mp> and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in the <z:chebi fb="20" ids="15767">DCM</z:chebi> heart </plain></SENT>
<SENT sid="7" pm="."><plain>Knockdown or downregulation of CYP2E1 might be a therapeutic strategy to control the development of <z:chebi fb="20" ids="15767">DCM</z:chebi> after mutations of cTnT(R141W) or other factors, because <z:chebi fb="20" ids="15767">DCM</z:chebi> is the third most common cause of <z:hpo ids='HP_0001635'>heart failure</z:hpo> and the most frequent cause of heart transplantation </plain></SENT>
</text></document>